Compare MXC & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MXC | QNCX |
|---|---|---|
| Founded | 1972 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.8M | 19.9M |
| IPO Year | 1995 | 2019 |
| Metric | MXC | QNCX |
|---|---|---|
| Price | $8.76 | $1.07 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.8K | ★ 1.5M |
| Earning Date | 02-10-2026 | 04-10-2026 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | ★ 30.65 | N/A |
| EPS | 0.30 | ★ 2.88 |
| Revenue | ★ $2,705,235.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $29.20 | ★ $0.38 |
| Revenue Growth | ★ 7.12 | N/A |
| 52 Week Low | $6.75 | $0.08 |
| 52 Week High | $16.48 | $4.55 |
| Indicator | MXC | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 39.26 | 49.22 |
| Support Level | $8.57 | $0.10 |
| Resistance Level | $9.65 | $1.50 |
| Average True Range (ATR) | 0.49 | 0.11 |
| MACD | -0.04 | -0.06 |
| Stochastic Oscillator | 0.57 | 50.00 |
Mexco Energy Corporation is an independent oil and gas company. It is engaged in the acquisition, exploration, development, and production of natural gas and crude oil properties located in the United States. The company carried out its operation in the Permian Basin of West Texas. It is focusing on two primary areas, the Delaware Basin located in the Western portion of the Permian Basin including Lea and Eddy Counties, New Mexico and Loving County, Texas, and the Midland Basin located in the Eastern portion of the Permian Basin including Reagan, Upton, Midland, Martin, Howard, and Glasscock Counties, Texas. The company generates revenue from Oil sales, Natural gas sales, oil and gas royalty interests.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.